AIM: To confirm the prognostic value of post-brachytherapy initial tumour regression rate in posterior uveal melanoma. METHODS: A prospective, comparative, observational cohort study was carried out on 147 eyes (147 patients) with choroidal melanoma (mean age 61 years) treated with Ru-106 brachytherapy. OBSERVATION PROCEDURE: Patients were followed clinically and ultrasonically every 6.7 (SD 0.3) months (1001 examinations). On average each patient was examined 5.8 times (mean follow up 9.6 (3.7) years). The echographic parameters included tumour base size, height, internal reflectivity, regularity, vascularity, and extrascleral extension. The clinical follow up included ocular examination and periodic metastatic screening (liver function tests and liver imaging). Main outcome measures were risk of liver metastasis in correlation with the post-brachytherapy initial tumour regression rate. RESULTS: At brachytherapy the mean tumour height was 5.2 mm (range 2.2-11.8 mm). After brachytherapy 142 tumours (96.6%) responded by a decrease in height. The initial height regression rate was 6.1% (0.8%) per month in patients who later developed metastasis v 4.3% (0.4%) per month in those who did not. Tumours higher than 6 mm, tumours with an internal reflectivity smaller than 50%, and tumours with an initial rate of height regression larger than 0.7 mm/month (10% per month) had higher 5 year melanoma related mortality. Kaplan-Meier survival analysis and the multivariate Cox proportional hazards model showed a significant role for tumour height and initial tumour regression rate on patients' survival. CONCLUSION: This study confirms that post-brachytherapy initial tumour regression rate has a prognostic value.
AIM: To confirm the prognostic value of post-brachytherapy initial tumour regression rate in posterior uveal melanoma. METHODS: A prospective, comparative, observational cohort study was carried out on 147 eyes (147 patients) with choroidal melanoma (mean age 61 years) treated with Ru-106 brachytherapy. OBSERVATION PROCEDURE: Patients were followed clinically and ultrasonically every 6.7 (SD 0.3) months (1001 examinations). On average each patient was examined 5.8 times (mean follow up 9.6 (3.7) years). The echographic parameters included tumour base size, height, internal reflectivity, regularity, vascularity, and extrascleral extension. The clinical follow up included ocular examination and periodic metastatic screening (liver function tests and liver imaging). Main outcome measures were risk of liver metastasis in correlation with the post-brachytherapy initial tumour regression rate. RESULTS: At brachytherapy the mean tumour height was 5.2 mm (range 2.2-11.8 mm). After brachytherapy 142 tumours (96.6%) responded by a decrease in height. The initial height regression rate was 6.1% (0.8%) per month in patients who later developed metastasis v 4.3% (0.4%) per month in those who did not. Tumours higher than 6 mm, tumours with an internal reflectivity smaller than 50%, and tumours with an initial rate of height regression larger than 0.7 mm/month (10% per month) had higher 5 year melanoma related mortality. Kaplan-Meier survival analysis and the multivariate Cox proportional hazards model showed a significant role for tumour height and initial tumour regression rate on patients' survival. CONCLUSION: This study confirms that post-brachytherapy initial tumour regression rate has a prognostic value.
Authors: Arthur J Mueller; William R Freeman; Ulrich C Schaller; Anselm Kampik; Robert Folberg Journal: Ophthalmology Date: 2002-12 Impact factor: 12.079
Authors: C Chiquet; J D Grange; L Ayzac; P Chauvel; L M Patricot; M Devouassoux-Shisheboran Journal: Br J Ophthalmol Date: 2000-01 Impact factor: 4.638
Authors: R H Silverman; R Folberg; H C Boldt; H O Lloyd; M J Rondeau; M G Mehaffey; F L Lizzi; D J Coleman Journal: Ultrasound Med Biol Date: 1997 Impact factor: 2.998
Authors: A J Mueller; D U Bartsch; R Folberg; M G Mehaffey; H C Boldt; M Meyer; L M Gardner; M H Goldbaum; J Pe'er; W R Freeman Journal: Arch Ophthalmol Date: 1998-01
Authors: T Aoyama; M J Mastrangelo; D Berd; F E Nathan; C L Shields; J A Shields; E L Rosato; F E Rosato; T Sato Journal: Cancer Date: 2000-10-01 Impact factor: 6.860
Authors: Kishan Gupta; Colin A McCannel; Mitchell Kamrava; James Lamb; Robert D Almanzor; Tara A McCannel Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-02-24 Impact factor: 3.117
Authors: Robert Folberg; Zarema Arbieva; Jonas Moses; Amin Hayee; Tone Sandal; Shrihari Kadkol; Amy Y Lin; Klara Valyi-Nagy; Suman Setty; Lu Leach; Patricia Chévez-Barrios; Peter Larsen; Dibyen Majumdar; Jacob Pe'er; Andrew J Maniotis Journal: Am J Pathol Date: 2006-10 Impact factor: 4.307
Authors: Jose S Pulido; Norbert G Campeau; Ernst Klotz; Andrew N Primak; Osama Saba; Kaan Gunduz; Herbert Cantrill; Diva Salomão; Cynthia H McCollough Journal: Clin Ophthalmol Date: 2008-06
Authors: Hakan Demirci; Fiorella Saponara; Adam Khan; Leslie M Niziol; Choonik Lee; James A Hayman; Grant Comer; David C Musch Journal: Middle East Afr J Ophthalmol Date: 2015 Jan-Mar